Rational Vaccines (RVx) was formed in 2015 for the purpose of offering better solutions to stop the spread of herpes and alleviate the problems faced by people suffering with unrelenting, chronic disease.
For decades, acyclovir-related antiviral drugs have been the standard of medical care for treating herpes and have failed to curb the symptoms of herpetic disease in many patients. Moreover, antiviral drugs have not curbed the epidemic spread of herpes simplex virus 1 and 2 (HSV-1 and HSV-2). Despite the availability of antiviral drugs, more than one million people continue to be newly infected with HSV-1 or HSV-2 every week.
Despite antiviral drugs, more than 1 million people are newly infected with HSV-1 or HSV-2 every week…
Because of the social stigma of “herpes,” patients often suffer in silence never telling friends or family they have the disease. For this reason, herpes has been described as a silent epidemic. Learn more about the three areas RVx will be targeting in our effort to improve the quality of care delivered to herpes patients.
RVx is developing the world’s first line of live HSV-1 and HSV-2 vaccines that bear attenuating mutations in the viral ICP0 protein, a critical positive regulator of HSV replication and reactivation. These live HSV ICP0– mutant vaccines, TheravaxHSV and ProfavaxHSV, appear to be up to 100 times more effective than conventional HSV subunit vaccines. Coupled with our novel flow-cytometry based diagnostic technology, the HSV ABVIC Test, RVx is offering several new opportunities to improve the management and/or prevention of herpetic disease.
Never once, in the history of medicine, has a live-and-appropriately-attenuated viral vaccine failed to stop the spread of its corresponding disease in the human population.
Live viral vaccines re-create every facet of a microbe’s life cycle, and fully prepare the human immune system to do battle with the natural pathogen. Live viral vaccines have been used to prevent the viral diseases of (1) smallpox, (2) yellow fever, (3) polio, (4) mumps, (5) measles, (6) rubella, and (7) chickenpox. Never once, in the history of medicine, has a live-and-appropriately-attenuated viral vaccine failed to stop the spread of its corresponding disease in the human population. Ten years of pre-clinical studies suggests the same will be true with herpes. Specifically, RVx’s Chief Science Officer, Dr. William Halford, has published ten papers and reviews that collectively indicate that the ProfavaxHSV vaccine offers the first viable approach capable of stopping the epidemic spread of HSV-1 and HSV-2 (reviewed in Halford, 2014).